Dementia and Alzheimer Disease

In the largest meta-analysis of patients with poststroke seizures, findings showed that those with early seizures had a greater mortality risk than those with late.

Among 443 episodes in 149 patients treated with different doses of BXCL501 over 12 weeks, the 60 mcg dose showed a reduction in agitation for the first and all treated episodes at 1 and 2 hours.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 22, 2023.

Leigh Charvet, PhD, professor of neurology at the NYU Grossman School of Medicine, talked about a trial that aims to address cognitive impairment in patients with long COVID through a unique, remote, and home-based treatment approach.

In honor of World Alzheimer Day, held September 21, 2023, get caught up on some of the latest news in Alzheimer disease as the NeurologyLive® team shares some of our data updates.

A study examining eligibility criteria for Alzheimer agent trials showed that a significant proportion of older adults with early cognitive impairment may not qualify for these therapies because of health conditions and other factors.

In a recent multisite analysis of 361 patients with REM sleep behavior disorder, 84% had neurological abnormalities in at least one domain observed.

The associate professor in the department of neurology at the University of Rochester provided insight on her presentation on psychosis in Parkinson disease and related disorders given at the 2023 ANA Annual Meeting.

The AIRAscore may help optimize the diagnostic process of neurodegenerative disorders by comparing brain structures with collected age- and gender-specific qualitative data samples.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer and dementia.

Positive findings from a phase 2b/3 study investigating blarcamesine, an investigational agent, demonstrated efficacy among patients with early Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 15, 2023.

Over a 2-year treatment period, patients on ALZ-801 demonstrated significant correlations between effects on volumetric MRI outcomes and 3 cognitive scales, suggesting cognitive gains are a result of preservation of brain structures from neurodegeneration and atrophy.

Findings from a recent exploratory study suggest that assessing daily functioning in a more sensitive way may identify Alzheimer disease before a patient develops more pronounced cognitive changes.

The combined preclinical and clinical data with neflamapimod suggest the therapy has potential to be the first disease-modifying treatment for dementia with Lewy Bodies, demonstrating a positive impact on cognition, function, and mobility.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Researchers developed a novel “closed-loop” system that delivered electrical pulses in a brain region to synchronize brain activity recorded from another region in the brain to improve memory.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 8, 2023.

Catch up on any of the neurology news headlines you may have missed over the course of September 2023, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 1, 2023.

A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]

Russell Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the ongoing collaboration focused on exploring the role of misfolded synuclein traditionally associated with Parkinson disease and in various forms of dementia.

Social determinants of health are conditions that people are born into and live under that affect their health, and can greatly impact clinical outcomes as well as contribute to health disparities and inequalities.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

The group of experts provided perspectives on the shift in how residency programs are developed and laid out, as well as efforts to increase the number of young neurologists in the field.

Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.